• Jenscare received Hong Kong Department of Health clearance for LuX-Valve Plus, its transvenous tricuspid valve replacement system.
• The group is pursuing commercialization in Hong Kong.
• LuX-Valve Plus is the world’s second cleared transvenous orthotopic tricuspid valve replacement system.
• The device has already secured regulatory clearances across parts of Europe, the Middle East, and Asia-Pacific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12322264), on September 04, 2026, and is solely responsible for the information contained therein.